ClinicalTrials.Veeva

Menu
R

Research Solutions of Arizona | Litchfield Park, AZ

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Mirikizumab
MK-7240
Guselkumab
IgPro20
Tulisokibart
S-600918
MK-7240-001
Remibrutinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 11 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Enrolling
Crohn's Disease
Drug: Mirikizumab

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will ha...

Active, not recruiting
Ulcerative Colitis Chronic
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: IV Placebo
Drug: SC Placebo

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Enrolling
Ulcerative Colitis
Drug: Mirikizumab

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: Placebo
Status recently updated

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Enrolling
Active, not recruiting
Hereditary Angioedema (HAE)
Biological: CSL312
Recently updated

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

Active, not recruiting
Hereditary Angioedema
Biological: CSL312

Trial sponsors

Lilly logo
CSL Behring logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
Novartis logo
Shionogi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems